IRVINE, Calif.--(BUSINESS WIRE)--Irvine-based Biogennix, an osteobiologics company that develops, manufactures, and distributes proprietary bone graft substitutes used for bone fusion procedures, announced today that it saw 33% growth for the first quarter of 2018, marking the company’s strongest quarter yet. This news follows on the heels of Biogennix’s record growth for 2017.
“The momentum we had coming into 2018 after a record year last year continues to mount,” said Scott Bauccio, Biogennix’s Vice President of Sales and Business Development. “Our Morpheus™ and osteoSPAN™ bone graft products fueled the 33% growth we saw in Q1 and we’re on a pace to replicate that success once again with our Q2 numbers. These products are fast becoming the new standard of effectiveness and ease of use in the bone graft substitute space.”
The majority of Biogennix’s steady growth is attributed to increases in sales of the company’s novel bone graft substitutes, Morpheus and osteoSPAN, both of which are resorbable, osteoconductive scaffolds ideally suited for bone regeneration. The Morpheus product is a moldable version of osteoSPAN, which combines the granules with an organic binder, providing optimal handling characteristics for surgeons.
Biogennix is a leading developer of osteobiologic products specifically designed for posterolateral spine and long bone fusion. The company is led by a team of scientists and industry veterans committed to delivering unique products for bone regeneration. Biogennix designs, manufactures and distributes all of its products from its Irvine facilities.
Biogennix™ is a fully-integrated osteobiologic company headquartered in Irvine which develops, manufactures, and distributes proprietary bone graft substitutes used in bone fusion procedures. Learn more at biogennix.com.